Pill Identifier App

Numira Biosciences and Visual Influence Announce Merger

IRVINE, Calif. and SALT LAKE CITY, February 02, 2007 /PRNewswire/ -- Numira Biosciences and Visual Influence today announced the merger of the two companies. As a result of the merger, Visual Influence is now a wholly-owned subsidiary of Numira.

"We are excited to combine the two companies and our respective technologies," said Michael Beeuwsaert, President and CEO, Numira Biosciences. "Through this combination, Numira will be better positioned to deliver more complete solutions and a broader range of leading-edge imaging products for the drug discovery research market."

Visual Influence will remain in Salt Lake City and its President, David Weinstein, Ph.D., will become Numira's Chief Technology Officer. "We look forward to developing a number of powerful, integrated products that leverage Numira's novel targeted reagent technologies with our visualization software capabilities," said Dr. Weinstein.

About Numira Biosciences:

Numira is a specialty R&D tools company focused on leveraging advances in genetics and molecular imaging to create a catalog of novel, high-value products that provide researchers with unprecedented insight into genomics, developmental biology, mechanisms of disease, drug efficacy and toxicity.

About Visual Influence:

Visual Influence is a spin-off company from the University of Utah's Scientific Computing and Imaging (SCI) Institute. The Company develops high-performance, custom rendering and image analysis software for medical imaging, scientific data management, image processing and analysis, volume visualization, and high-performance computing.

For more information, please visit www.numirabio.com.

CONTACT: Michael Beeuwsaert, President & CEO of Numira Biosciences Inc.,+1-949-623-8603, mbeeuwsaert@numirabio.com

Web site: http://www.numirabio.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: February 2007


View comments

Hide
(web3)